[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341261-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341261-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","proteomic-analysis-reveals-trilaciclib-induced-senescence","Proteomic Analysis Reveals Trilaciclib-Induced Senescence","","Mass spectrometry-based proteomics was used to examine the CDK4/6 inhibitor trilaciclib across hematological cancer cell lines. Trilaciclib promoted autophagy-associated senescence in chronic myeloid leukemia cells, rather than inducing cell death, while similar senescence effects were observed in acute myeloid leukemia, acute lymphoblastic leukemia, and myeloma models. In K562 cells, trilaciclib reduced proliferation by hindering cell cycle progression, stabilizing CDK4/6, downregulating cell-cycle proteins, and activating autophagy pathways. Senescence induction was also detected in the NSCLC A549 line, supporting its therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/proteomic-analysis-reveals-trilaciclib-induced-senescence/341261/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/proteomic-analysis-reveals-trilaciclib-induced-senescence/341261.png","ImageObject",300,407,{"name":42,"@type":43},"Violet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What did proteomic analysis reveal about trilaciclib’s effect on hematological cancer cells?","Question",{"text":63,"@type":64},"Proteomics showed that trilaciclib triggers autophagy-induced senescence, altering viability and cell proliferation in hematological cancer cell lines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does trilaciclib act in chronic myeloid leukemia models compared with acute leukemia and myeloma?",{"text":68,"@type":64},"In chronic myeloid leukemia cells, trilaciclib promotes autophagy-associated senescence rather than inducing cell death, and senescence is also observed in acute leukemia and myeloma cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What molecular changes accompany trilaciclib-induced senescence in K562 cells?",{"text":72,"@type":64},"Trilaciclib hindered cell cycle progression and proliferation by stabilizing CDK4/6 and downregulating cell-cycle-related proteins, alongside activation of autophagy pathways.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341261,1790177488,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Proteomic Analysis Reveals Trilaciclib-Induced Senescence  \nAuthors  \nMarina Hermosilla-Trespaderne, Mark Xinchen Hu-Yang, Abeer Dannoura, Andrew M. Frey, Amy L. George, Matthias Trost, and Jos´e Luis Marín-Rubio  \nCorrespondence [matthias.trost@ncl.ac.uk](matthias.trost@ncl.ac.uk) ; [marinrj@mskcc.org](marinrj@mskcc.org)  \nIn Brief  \nUsing mass spectrometry-based proteomics, we analyzed the CDK4/6 inhibitor, trilaciclib, across hematological cancer cell lines. Trilaciclib promotes autophagy-induced senescencein chronic myeloid leukemia, diverging from cell death induction in acute myeloid leukemia, acute lymphoblastic  \nleukemia, and myeloma. Moreover, trilaciclib induces senescence in nonsmall cell lung carcinoma cell line (A549), broadening its scope in cancer treatment. Our ﬁndings highlight the need for balanced senescence and cell death induction, showcasing trilaciclib's therapeutic potential.  \nGraphical Abstract  \nHighlights  \n• Trilaciclib affects the viability and cell proliferation of hematological cancer cells.  \n• Trilaciclib exhibits a dual role in both cell death and senescence.  \n• Proteomics unveils that trilaciclib triggers autophagy-induced senescence.  \n2024, Mol Cell Proteomics 23(6), 100778  \n© 2024 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY-NC-ND license ([http://](http://)[ ](http://)[creativecommons.org/licenses/by-nc-nd/4.0/](creativecommons.org/licenses/by-nc-nd/4.0/)).  \n[https://doi.org/10.1016/j.mcpro.2024.100778](https://doi.org/10.1016/j.mcpro.2024.100778)  \n RESEARCH ARTICLE COLLECTION: CANCER PROTEOMICS  \n| Proteomic Analysis Reveals Trilaciclib-Induced Senescence\u003Cbr>Marina Hermosilla-Trespaderne 1 ,2 ,‡, Mark Xinchen Hu-Yang 1 ,2 ,‡, Abeer Dannoura 1,\u003Cbr>Andrew M. Frey1 , Amy L. George 1 , Matthias Trost 1 ,* , and Jos´e Luis Marín-Rubio 1 ,3 ,* ,‡ |  |\n| --- | --- |\n| Trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, was approved as a myeloprotective agent for protecting bone marrow from chemotherapy-induced damage in extensive-stage small cell lung cancer. This is achieved through the induction of a temporary halt in the cell cycle of bone marrow cells. While it has been studied in various cancer types, its potential in hematological cancers remains unexplored. This research aimed to investigate the efﬁcacy of trilaciclib in hematological cancers. Utilizing mass spectrometry-based proteomics, we examined the alterations induced by trilaciclib in the chronic myeloid leukemia cell line, K562. Interestingly, trilaciclib promoted senescence in these cells rather than cell death, as observed in acute myeloid leukemia, acute lymphoblastic leukemia, and myeloma cells. In K562 cells, trilaciclib hindered cell cycle progression and proliferation by stabilizing cyclin-dependent kinase 4/6 and downregulating cell cycle–related proteins, along with the concomitant activation of autophagy pathways. Additionally, trilaciclibinduced senescence was also observed in the nonsmall cell lung carcinoma cell line, A549. These ﬁndings highlight trilaciclib's potential as a therapeutic option for hematological cancers and underscore the need to carefully balance senescence induction and autophagy modulation in chronic myeloid leukemia treatment, as well as in nonsmall cell lung carcinoma cell line.\u003Cbr>Trilaciclib was approved by the FDA in 2021 as a myeloprotective agent for adult patients with extensive-stage small cell lung cancer (1 , 2) . Trilaciclib is given prior to the administration of chemotherapy in order to prepare and protect the bone marrow from the potential damage caused by the chemotherapy treatment. Trilaciclib blocks cyclindependent kinase 4 (CDK4) and CDK6, which plays a crucial role in cell cycle progression, particularly in the transition from the G1 phase to the S phase. Clinical trials have evaluated the use of trilaciclib in various cancer types, including small cell lung ca","cbCaisiGYLDoHNbB","https://ap.wps.com/l/cbCaisiGYLDoHNbB","pdf",4345774,14,"English","# In Brief\n# Graphical Abstract\n# Highlights\n## Dual role of trilaciclib\n# Research Article Collection: Cancer Proteomics\n## Background and rationale\n## Methods and proteomics approach\n## Results in CML and other hematological models","[{\"question\":\"What did proteomic analysis reveal about trilaciclib’s effect on hematological cancer cells?\",\"answer\":\"Proteomics showed that trilaciclib triggers autophagy-induced senescence, altering viability and cell proliferation in hematological cancer cell lines.\"},{\"question\":\"How does trilaciclib act in chronic myeloid leukemia models compared with acute leukemia and myeloma?\",\"answer\":\"In chronic myeloid leukemia cells, trilaciclib promotes autophagy-associated senescence rather than inducing cell death, and senescence is also observed in acute leukemia and myeloma cells.\"},{\"question\":\"What molecular changes accompany trilaciclib-induced senescence in K562 cells?\",\"answer\":\"Trilaciclib hindered cell cycle progression and proliferation by stabilizing CDK4/6 and downregulating cell-cycle-related proteins, alongside activation of autophagy pathways.\"}]","Proteomic Analysis Reveals Trilaciclib-Induced Senescence | PDF",1790041185,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8cdcd7b46ad93551ca432ca01bf01a7.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/482d6dc16515d1309a4660a44a84dc9e.webp",982,1294,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7443c5b0398556d5f7039f9b5b41a69.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35534f852f3eb27e2f6813312c43130b.webp",980,1292]